is retatrutide on the market ๐๏ธ NEW EPISODE: RetatrutideโThe Triple Agonist *Not licensed* Will this replace current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) showing unprecedented results in RetatrutideโA Game Changer in Obesity
Description
not independently verified
Depending on the procedure they choose, patients can expect to lose roughly 25% to 35% of their total body weight
Learn more about accessing weight loss prescriptions online through telehealth
However, changes in epicardial fat density, which may reflect alterations in adipose tissue biology rather than size alone, was linked to improved outcomes
Gut microbiotas and host evolution: scaling up Symbiosis
doi: 10.1001/jamapsychiatry.2025.4308
